Erratum to: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications

Archives of Gynecology and Obstetrics ◽

10.1007/s00404-016-4035-8 ◽

2016 ◽

Vol 293 (4) ◽

pp. 695-700 ◽

Cited By ~ 73

Author(s):

Ivo Meinhold-Heerlein ◽

Christina Fotopoulou ◽

Philipp Harter ◽

Christian Kurzeder ◽

Alexander Mustea ◽

...

Keyword(s):

Fallopian Tube ◽

Who Classification ◽

Clinical Implications ◽

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

Annals of Oncology ◽

10.1093/annonc/mdx445 ◽

2017 ◽

Vol 28 ◽

pp. viii8-viii12 ◽

Cited By ~ 10

Author(s):

L.R. Duska ◽

E.C. Kohn

Keyword(s):

Fallopian Tube ◽

Clinical Implications ◽

Improved Optimal Cytoreduction Rates for Stages IIIC and IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: A Change in Surgical Approach

Yearbook of Obstetrics Gynecology and Women s Health ◽

10.1016/s1090-798x(08)70606-4 ◽

2006 ◽

Vol 2006 ◽

pp. 466-467

Author(s):

G. Rodriguez

Keyword(s):

Fallopian Tube ◽

Surgical Approach ◽

Optimal Cytoreduction ◽

PREDICTING OUTCOME IN EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER ACCORDING TO HISTOLOGICAL TUMOUR RESPONSE TO NEO-ADJUVANT CHEMOTHERAPY, AT THE TIME OF INTERVAL DEBULKING.

10.26226/morressier.5770e29cd462b80290b4c049 ◽

2016 ◽

Author(s):

Sinead Barry

Keyword(s):

Adjuvant Chemotherapy ◽

Fallopian Tube ◽

Tumour Response ◽

Peritoneal Cancer ◽

Predicting Outcome ◽

Neo Adjuvant Chemotherapy

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Case Medical Research ◽

10.31525/ct1-nct03907527 ◽

2019 ◽

Author(s):

Keyword(s):

T Cells ◽

Fallopian Tube ◽

Immune Cells ◽

Peritoneal Cancer ◽

Car T Cells ◽

Platinum Resistant ◽

Car T

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.017 ◽

2011 ◽

Vol 2011 ◽

pp. 78-79

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Clinical Activity ◽

Fallopian Tube Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian, fallopian tube and/or primary peritoneal cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012567 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob P Hoogendam ◽

Joline F Roze ◽

Fleur T van de Wetering ◽

René Spijker ◽

Leen Verleye ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Positron Emission Tomography ◽

Magnetic Resonance ◽

Fallopian Tube ◽

Emission Tomography ◽

Resonance Imaging ◽

Peritoneal Cancer ◽

Positron Emission ◽

Magnetic Resonance Imaging Mri

CYTOREDUCTIVE SURGERY (CRS) AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN PATIENTS WITH ADVANCED OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: OUR EXPERIENCE IN 108 PATIENTS

10.26226/morressier.5d2ee8eb1e09a6f49485abf9 ◽

2019 ◽

Author(s):

Mihai Emil Capilna ◽

MIHAI GHEORGHE ◽

Szilard Leo Kiss ◽

Alexandra Lavinia Cozlea

Keyword(s):

Fallopian Tube ◽

Intraperitoneal Chemotherapy ◽

Cytoreductive Surgery ◽

Hyperthermic Intraperitoneal Chemotherapy ◽

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70363-2 ◽

2013 ◽

Vol 14 (10) ◽

pp. 1020-1026 ◽

Cited By ~ 264

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Seiji Isonishi ◽

Fumiaki Takahashi ◽

Hirofumi Michimae ◽

...

Keyword(s):

Fallopian Tube ◽

Long Term Results ◽

Open Label ◽

Peritoneal Cancer ◽

Open Label Trial ◽

Dose Dense ◽

Randomised Controlled

Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000413 ◽

2018 ◽

Vol 41 (10) ◽

pp. 938-942 ◽

Cited By ~ 3

Author(s):

Vaagn Andikyan ◽

Annie Kim ◽

Herbert F. Gretz ◽

Konstantin Zakashansky ◽

Monica Prasad-Hayes ◽

...

Keyword(s):

Fallopian Tube ◽

Optimal Cytoreduction ◽

Debulking Surgery ◽

Peritoneal Cancer ◽

Primary Debulking Surgery